Osteoprotegerin serum levels in women: Correlation with age, bone mass, bone turnover and fracture status

Wiener Klinische Wochenschrift

Volumn 115, Issue 9, 2003, Pages 291-297

  Fahrleitner Pammer, Astrid ^a,b   Dobnig, Harald ^a   Piswanger Soelkner, Claudia ^a   Bonelli, Christine ^a   Dimai, Hans Peter ^a   Leb, Georg ^a   Obermayer Pietsch, Barbara ^a  

^a UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY HOSPITAL GRAZ   (Austria)

Author keywords

Bone mass; Bone turnover; Fracture risk; Osteoprotegerin; RANKL

Indexed keywords

BIOCHEMICAL MARKER; COLLAGEN TYPE 1; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ADULT; AGED; AGING; ARTICLE; BLOOD LEVEL; BONE CELL; BONE MASS; BONE TURNOVER; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; FEMALE; FRACTURE; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; OSTEOLYSIS; OSTEOPOROSIS; PARACRINE SIGNALING; RISK FACTOR; VERTEBRA FRACTURE;

EID: 0038540824     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03040334     Document Type: Article

References (31)

1. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, et al (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89: 309-319
2. Tsuda E, Goto M, Mochizuki S, Yano K, Kobayashi F, Morinaga T, et al (1997) Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 234: 137-142
3. The American Society for Bone and Mineral Research president's comittee on nomenclature (2000) Proposed standard nomenclature for new tumor necrosis factor family members involved in the regulation of bone resorption. J Bone Miner Res 15: 2293-2296
4. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165-176
5. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, et al (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis - inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95: 3597-3602
6. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL (2000) The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 15: 2-12
7. Hofbauer LC, Heufelder AE (2000) The role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone disease. J Clin Endocrinol Metab 85: 2355-2363
8. Kong YY, Penninger JM (2000) Molecular control of bone remodeling and osteoporosis. Exp Gerontol 35: 947-956
9. Hakeda Y, Kobayashi Y, Yamaguchi K, Yasuda H, Tsuda E, Higashio K, et al (1998) Osteoclastogenesis inhibitory factor (OCIF) directly inhibits bone-resorbing activity of isolated mature osteoclasts. Biochem Biophys Res Com 251: 796-801
10. Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T, et al (1998) Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 247: 610-615
11. Min H, Morony S, Sarosi I, Dunstan CR, Capparelli C, Scully S, et al (2000) Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 192: 463-474
12. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, et al (1998) Osteoprotegerin deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12: 1260-1268
13. Yano K, Tsuda E, Washida N, Kobayashi F, Goto M, Harada A, et al (1999) Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: Increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res 14: 518-527
14. Khosla S, Arrighi HM, Melton LJ, Atkinson EJ, O'Fallon WM, Dunstan C, et al (2001) Correlates of osteoprotegerin levels in women and men. Osteoporos Int 13: 394-399
15. Browner WS, Lui LY, Cummings S (2001) Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures and mortality in elderly women. J Clin Endocrinol Metab 86: 631-637
16. Szulc P, Hofbauer LC, Heufelder AE, Roth S, Delmas PD (2001) Osteoprotegerin serum levels in men: correlation with age, estrogen and testosterone status. J Clin Endocrinol Metab 86: 3162-3165
17. Haas M, Leko-Mohr Z, Roschger P, Kletzmayr J, Schwarz, C, Domenig C, et al (2002) Osteoprotegerin and parathyroid hormone as markers of high-turnover osteodystrophy and decreased bone mineralization in hemodialysis patients. Am J Kidney Dis 39: 580-586
18. Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR (2001) The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 16: 348-360
19. Kanis JA (1997) The diagnosis of osteoporosis. Osteoporos Int 7 [Suppl 3]: S1-5
20. Husdan H, Rapoport A, Locke S, Oreopoulos D (1976) More on adjusting serum Ca for protein. Clin Chem 22: 933-934
21. Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 16: 348-360
22. Makhulf HA, Mueller SM, Mizuno S, Glowacki J (2000) Age-related decline in osteoprotegerin expression by human bone marrow cells cultured in three-dimensional collagen sponges. Biochem Biophys Res Commun 268: 669-672
23. Fahrleitner A, Prenner G, Kniepeiss D, Iberer F, Tscheliessnigg KH, Piswanger-Sölkner C, et al (2002) Serum osteoprotegerin levels in patients after liver transplantation and correlation to bone turnover, bone mineral density and fracture status. Wien Klin Wochenschr 114: 717-724
24. Fahrleitner A, Prenner G, Leb G, Tscheliessnigg KH, Piswanger-Sölkner C, Obermayer-Pietsch B, et al (2003) Serum osteoprotegerin is a major determinant of bone density and vertebral fracture status in patients after cardiac transplantation. Bone 32: 96-106
25. Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N, et al (1998) Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139: 1329-1337
26. Wong BR, Josien R, Choi Y (1999) TRANCE is a TNF family member that regulates dendritic cell and osteoclast function. J Leucocyte Biol 65: 715-724
27. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, et al (1999) OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymp-node organogenesis. Nature 397: 315-323
28. Bu R, McKeon RM, Cao L, Blair HC (2001) Osteoprotegerin (OPG) binds TNF family proteins including TNFα and protects osteoblasts from TNFα-induced apoptosis: a complementary function in addition to effects of OPG on osteoclast differentiation via RANKL. J Bone Miner Res 16 [Suppl 1]: S169 (Abstract)
29. Holt MI, Baattrup A, Eriksen EF (2001) Expression of osteoclast differentiating factor (ODF, RANKL) and osteoprotegerin (OPG) in human bone: role of the bone remodeling compartment in the coupling between resorption and formation. J Bone Miner Res 16 [Suppl 1]: S364 (Abstract)
30. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spelsberg TC, Riggs BL (1999) Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 140: 4367-4370
31. Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC, et al (1999) Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 140: 4382-4389